En Carta Diagnostics vs ImmunoScape
En Carta Diagnostics vs ImmunoScape, compared side by side on 16 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: En Carta Diagnostics is on 52/100 and ImmunoScape on 58/100.
Where each one leads
En Carta Diagnostics
Leads on none of the measures we hold for both companies.
ImmunoScape
- our overall score: 58/100 against 52/100
- domain rating: 28/100 against 0/100
- funding raised: $49.7M against $5.0M
- LinkedIn following: 4,364 against 2,091
At a glance
| Measure | En Carta Diagnostics | ImmunoScape |
|---|---|---|
| What it is | Developing a new generation of molecular diagnostics for at-home use, combining laboratory accuracy with rapid test simplicity. | Developing novel immunotherapies and diagnostics for cancer. |
| Category | Biotechnology, HealthTech, Diagnostics, Medical Devices | Biotechnology, Cancer, Immunotherapy, Diagnostics |
| Sells toBusiness model | B2B2C | B2B |
| Offering | Hardware | Platform |
| Founded | 2022 | 2017 |
| Headquarters | Paris, France | Singapore, Singapore |
| Status | Inactive | Active |
Size, funding and growth
| Measure | En Carta Diagnostics | ImmunoScape |
|---|---|---|
| Employees | 12 | Not published |
| Total funding | $5.0M | $49.7M |
| Latest round | Seed | Series B2 |
| Valuation | Not published | $1.1B |
| LinkedIn followers | 2,091 | 4,364 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | En Carta Diagnostics | ImmunoScape |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 52/100 | 58/100 |
| Traction | 45/100 | 38/100 |
| Team | 70/100 | 70/100 |
| Search visibility | 20/100 | 23/100 |
| Quality | 58/100 | 68/100 |
| Agent readinessHow well an AI agent can read and act on the site | Not published | F (39/100) |
| Domain ratingLink authority, 0-100 | 0/100 | 28/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | En Carta Diagnostics | ImmunoScape |
|---|---|---|
| CDN | Not detected | Cloudflare |
| CMS | Not detected | WordPress |
| Frameworks | Not detected | Jquery |
| Analytics | Not detected | Google Tag Manager |
What users say
| Measure | En Carta Diagnostics | ImmunoScape |
|---|---|---|
| Reddit sentimentThreads we track | Not published | 6 positive, 0 negative across 6 threads |
“Singapore-based ImmunoScape Pioneers Next-Generation Cell Therapy for Solid Tumors; Announces Key Licensing Deal, New Board and SAB Appointments.”r/Quantisnow
En Carta Diagnostics vs ImmunoScape: common questions
Which is better, En Carta Diagnostics or ImmunoScape?
On our 0-100 score ImmunoScape rates higher (58/100 against 52/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 16 data points above: read the rows that match what you are buying for.
How do En Carta Diagnostics and ImmunoScape compare on the numbers?
ImmunoScape leads on our overall score (58/100 against 52/100), domain rating (28/100 against 0/100), funding raised ($49.7M against $5.0M), LinkedIn following (4,364 against 2,091).
What do real users say about En Carta Diagnostics and ImmunoScape?
ImmunoScape: 6 positive and 0 negative mentions across 6 Reddit threads we track, mostly in r/Quantisnow.
Read the full En Carta Diagnostics review and pricing or the ImmunoScape review and pricing. You can also browse other En Carta Diagnostics alternatives we track.